医药生物（A股）上市公司市值战略研究报告（2024年报）-和君咨询

Group 1 - The report analyzes the strategic management of market capitalization for A-share pharmaceutical and biotechnology companies in 2024, indicating a rebound in the industry but a slow recovery of indices, with a total market capitalization of 6.6 trillion yuan, accounting for 6.62% of A-shares [1][19][22] - The industry is characterized by "low profit, high P/E ratio," but the "high valuation" feature is weakening, with the overall score for value creation at 45.65, below the levels of 2022-2023 [1][25][14] - The report highlights six core areas of regulatory focus to support innovative drugs, emphasizing the need for innovation-driven changes in market structure and industry transformation, with record approvals for innovative drugs and devices [1][16][17] Group 2 - The essence of market capitalization management is to "create value and raise expectations," with a focus on value creation, shaping, and management, indicating a need for companies to optimize strategies to enhance market performance [1][32][14] - The report provides recommendations for market capitalization management, including solidifying value foundations, refining investment value labels, and enriching management tools, while noting significant challenges and clear differentiation within the industry [2][15] - The report identifies a need for improved communication and compliance in investor relations to stabilize market expectations, as overall performance growth and investment return certainty are declining [15][46][47]